Hologic, Inc. (HOLX) Director Namal Nawana Acquires 6,600 Shares
Hologic, Inc. (NASDAQ:HOLX) Director Namal Nawana purchased 6,600 shares of the stock in a transaction on Tuesday, February 13th. The shares were purchased at an average cost of $37.88 per share, with a total value of $250,008.00. Following the transaction, the director now owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded up $0.23 during midday trading on Wednesday, hitting $38.03. The stock had a trading volume of 3,320,590 shares, compared to its average volume of 3,012,295. Hologic, Inc. has a 52 week low of $35.33 and a 52 week high of $46.80. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98. The stock has a market capitalization of $10,519.17, a P/E ratio of 10.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.77.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The company had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same quarter in the prior year, the business earned $0.52 earnings per share. The company’s revenue was up 7.7% compared to the same quarter last year. sell-side analysts expect that Hologic, Inc. will post 2.25 earnings per share for the current fiscal year.
A number of equities research analysts have issued reports on the company. Canaccord Genuity reissued a “buy” rating and set a $48.00 price target on shares of Hologic in a research report on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and set a $50.00 price target on shares of Hologic in a research report on Friday, February 9th. Stifel Nicolaus downgraded Hologic from a “buy” rating to a “hold” rating and lowered their price target for the company from $45.00 to $42.00 in a research report on Friday, February 9th. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday. Finally, Royal Bank of Canada reissued a “hold” rating and set a $44.00 price target on shares of Hologic in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $48.00.
WARNING: This report was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/14/hologic-inc-holx-director-namal-nawana-acquires-6600-shares.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.